Literature DB >> 1670707

Rectal apomorphine in Parkinson's disease.

A J Hughes, S Bishop, A J Lees, G M Stern, R Webster, M Bovingdon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1670707     DOI： 10.1016/0140-6736(91)90780-s

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

Authors:  R van der Geest; T van Laar; J M Gubbens-Stibbe; H E Boddé; M Danhof
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

Review 4.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

5.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

Review 6.  Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.

Authors:  Nrupa Borkar; Huiling Mu; René Holm
Journal:  Asian J Pharm Sci       Date:  2017-12-06       Impact factor: 6.598

Review 7.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.